CA9 and renal cell carcinoma: Some examples include the ability of NK-92 cells expressing an ErbB2 (Her2)-specific CAR to reduce lung metastasis in a RCC model [208], how the combination of cabozantinib and NK-92 cells expressing an EGFR-specific CAR exhibit synergistic therapeutic efficacy against the human RCC xenograft model [209], and how bortezomib improves adoptive CAIX-specific CAR-modified NK-92 cell therapy in mouse models of RCC as well [210].